Advertisement
AXON vs BEAM
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Beam Therapeutics (BEAM) Stock Comparison
Key Takeaways
- Tickeron AI Verdict: On the basis of recent trend consistency, momentum, and catalyst positioning, Tickeron's AI currently favors BEAM over AXON.
- AXON is a profitable, fast-growing public-safety technology leader that recently missed estimates and cut guidance, triggering a sharp selloff.
- BEAM is a clinical-stage biotechnology company whose shares have risen on a series of positive pipeline and regulatory milestones.
- The two companies carry very different risk profiles: AXON offers established recurring revenue, while BEAM remains a pre-profit, catalyst-driven biotech.
- Relative performance has diverged notably in recent weeks, with BEAM showing positive momentum as AXON's uptrend broke down.
- For more detail, explore AXON Major News and AXON Today's Price Move, plus BEAM Major News and BEAM Today's Price Move.
- To see how AI trading systems are positioning across the market, explore Trending AI Robots.
Introduction
This stock comparison places two very different businesses side by side: Axon Enterprise, a profitable public-safety hardware and software provider, and Beam Therapeutics, a clinical-stage genetic-medicine company. The contrast is useful for investors deciding between an established growth leader with recurring revenue and a higher-risk biotech whose value hinges on clinical and regulatory milestones. Because their market positioning and risk drivers are so distinct, comparing their recent price behavior and relative performance helps clarify how momentum, sentiment, and catalysts are currently diverging between the two tickers.
AXON Overview and Recent Performance
Axon Enterprise (AXON) sells TASER conducted-energy devices, body cameras, and a growing software ecosystem for law enforcement and public safety, and has expanded into counter-drone technology. In its most recent quarter, revenue rose about 28% year over year to roughly $909 million, driven by 43% growth in Software & Services. Annual recurring revenue (ARR, or contracted subscription revenue) climbed about 40% to $1.75 billion, and AI-related ARR surpassed $100 million. However, the company missed consensus revenue and adjusted earnings estimates and lowered its full-year revenue outlook, citing delays in three federal counter-drone deployments. It also announced a $1.2 billion additional investment in drone maker Skydio. These factors triggered a sharp single-session decline, and the stock has fallen substantially over 2026, underperforming the broader market as sentiment shifted around hardware margins and the timing of large government contracts.
BEAM Overview and Recent Performance
Beam Therapeutics (BEAM) is a biotechnology company developing precision genetic medicines using base-editing technology. Its shares have gained ground in recent months on a steady flow of clinical and regulatory news. The company reported durable, positive data for BEAM-302 in alpha-1 antitrypsin deficiency (AATD, a genetic lung and liver condition) and is pursuing an accelerated approval pathway. It also presented early proof-of-concept data for BEAM-301 in glycogen storage disease type 1a (GSDIa), received U.S. Food and Drug Administration (FDA) clearance to begin clinical testing of BEAM-304 for phenylketonuria (PKU, an inherited metabolic disorder), and remains on track to submit a biologics license application (BLA, a request for marketing approval) for its sickle cell disease candidate risto-cel. Beam ended its most recent quarter with roughly $1.2 billion in cash, which management expects to fund operations into mid-2029. The company remains unprofitable, generating most revenue from collaboration agreements, so its valuation is closely tied to trial outcomes.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading systems. Tickeron maintains hundreds of AI trading bots that monitor thousands of different tickers, but only those best suited to current market conditions earn a place in this section. These bots vary widely in trading style, strategy, timeframe, performance history, and the sets of tickers they trade, so the list is continuously filtered to surface the most relevant opportunities. For traders who want a data-driven, hands-off perspective on names like AXON and BEAM, exploring the Trending AI Robots can provide an additional analytical layer beyond manual research.
Head-to-Head Comparison
The clearest contrast is the stage of each business. AXON is a scaled, profitable enterprise with a large base of recurring software revenue, but its recent performance has been pressured by margin compression, inventory investment, and unpredictable federal contract timing. BEAM, by contrast, generates little product revenue and remains dependent on clinical milestones, yet its momentum has been positive as catalysts accumulated. Sector exposure also differs sharply: AXON sits at the intersection of public safety and AI-driven hardware, while BEAM is exposed to biotechnology risk, including regulatory and clinical-trial outcomes. On momentum, BEAM has trended upward in recent weeks, whereas AXON's trend has deteriorated after breaking key levels. For investors, the trade-off is between AXON's established cash flows at a compressed valuation and BEAM's higher-risk, catalyst-driven upside.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, and the near-term catalyst picture, Tickeron's AI would likely favor BEAM in the current environment. Beam's price trend has held up more consistently, supported by a sequence of positive clinical and regulatory updates, while Axon's trend has been disrupted by an earnings miss, a guidance reduction, and lingering margin concerns. This assessment reflects relative positioning and momentum rather than any definitive claim about future returns, and it is offered in probabilistic terms rather than as investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and BEAM is a StrongBuy.
AXON's RSI Oscillator descends into oversold zone
The RSI Indicator for AXON moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 55 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 32 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
BEAM in upward trend: 10-day moving average broke above 50-day moving average on November 03, 2026
The 10-day moving average for BEAM crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BEAM as a result. In 66 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
BEAM moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 198 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for BEAM moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 56 cases where BEAM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
BEAM broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.555) is normal, around the industry mean (3.498). P/E Ratio (-38.275) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AXON | BEAM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 80 | 100 | |
SMR RATING 1..100 | 81 | 92 | |
PRICE GROWTH RATING 1..100 | 65 | 53 | |
P/E GROWTH RATING 1..100 | 81 | 47 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BEAM's Valuation (5) in the null industry is significantly better than the same rating for AXON (90) in the Biotechnology industry. This means that BEAM’s stock grew significantly faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as BEAM (100) in the null industry. This means that AXON’s stock grew similarly to BEAM’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as BEAM (92) in the null industry. This means that AXON’s stock grew similarly to BEAM’s over the last 12 months.
BEAM's Price Growth Rating (53) in the null industry is in the same range as AXON (65) in the Biotechnology industry. This means that BEAM’s stock grew similarly to AXON’s over the last 12 months.
BEAM's P/E Growth Rating (47) in the null industry is somewhat better than the same rating for AXON (81) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than AXON’s over the last 12 months.
| AXON | BEAM | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 86% | 4 days ago 84% |
| Stochastic ODDS (%) | 4 days ago 82% | 4 days ago 80% |
| Momentum ODDS (%) | 4 days ago 72% | 4 days ago 80% |
| MACD ODDS (%) | 4 days ago 84% | N/A |
| TrendWeek ODDS (%) | 4 days ago 69% | 4 days ago 82% |
| TrendMonth ODDS (%) | 4 days ago 71% | 4 days ago 77% |
| Advances ODDS (%) | 14 days ago 74% | 6 days ago 76% |
| Declines ODDS (%) | 4 days ago 70% | 8 days ago 84% |
| BollingerBands ODDS (%) | 4 days ago 79% | 4 days ago 76% |
| Aroon ODDS (%) | 4 days ago 80% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while BEAM’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- BEAM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while BEAM’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 4 bearish.
- BEAM’s TA Score: 4 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -26.83% price change this week, while BEAM (@Biotechnology) price change was -3.01% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +2.89%. For the same industry, the average monthly price growth was -3.78%, and the average quarterly price growth was -16.05%.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
AXON is expected to report earnings on Mar 02, 2027.
BEAM is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Aerospace & Defense (+2.89% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AXON and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | -18.18% | ||
| TECH - AXON | 61% Loosely correlated | +0.17% | ||
| VCYT - AXON | 58% Loosely correlated | +0.67% | ||
| BEAM - AXON | 57% Loosely correlated | +2.09% | ||
| SEER - AXON | 56% Loosely correlated | N/A | ||
| ADPT - AXON | 56% Loosely correlated | +4.29% | ||
More | ||||
BEAM and
Correlation & Price change
A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To BEAM | 1D Price Change % | ||
|---|---|---|---|---|
| BEAM | 100% | +2.09% | ||
| CRSP - BEAM | 77% Closely correlated | +3.11% | ||
| EDIT - BEAM | 67% Closely correlated | +0.78% | ||
| NTLA - BEAM | 67% Closely correlated | +2.25% | ||
| PRME - BEAM | 65% Loosely correlated | +4.49% | ||
| RXRX - BEAM | 60% Loosely correlated | +0.57% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TLG | 23.96 | 0.39 | +1.64% |
| Touchstone Large Company Growth ETF (TLG) | |||
| JMHI | 48.67 | 0.13 | +0.27% |
| JPMorgan High Yield Municipal ETF (JMHI) | |||
| TEUP | 8.70 | N/A | N/A |
| T-REX 2X Long TE Daily Target ETF (TEUP) | |||
| BDVG | 14.90 | -0.04 | -0.25% |
| iMGP Berkshire Dividend Growth ETF (BDVG) | |||
| FYX | 136.73 | -0.39 | -0.28% |
| First Trust Small Cap Core Alphadex Fund (FYX) | |||